Skip to main content
SpringerLink
Log in

Antipsychotische Wirksamkeit des atypischen Neuroleptikums Amisulprid auf Positiv- und Negativsymptomatik

  • Chapter
Universitätskolloquien zur Schizophrenie

Zusammenfassung

Mit den modernen Antipsychotika verbinden sich große Hoffnungen hinsichtlich der Therapie schizophrener Erkrankungen: Die im Vergleich zu klassischen Neuroleptika bessere extrapyramidalmotorische Verträglichkeit und bessere Wirksamkeit auf die Negativsymptomatik sowie eventuell auch ausgeprägteren Effekte auf Depressivität und kognitive Störungen sollen zu einer günstigeren Beeinflussung des Krankheitsverlaufs und zu einer höheren Lebensqualität der Patienten führen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adler G (2001) Amisulpride in patients with chronic schizophrenia: comparison with other atypical antipsychotics. World J Biol Psychiatry 2 (Suppl 1): 311S

    Google Scholar 

  2. Adler G, Weber D, Grieshaber S, Schmitt A, Dressing H (2000) Atypical antipsychotics and memory function in patients with chronic schizophrenia. Int J Neuropsychopharmacol 3 (Suppl 1): S165

    Google Scholar 

  3. Agelink MW, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T, Klieser E (2001) Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 21: 8–13

    Article  PubMed  CAS  Google Scholar 

  4. Allison DB, Mentore JL, Heo M, Weiden PJ, Cappellerie J, Chandler LP (1997) Weight gain associated with conventional and newer antipsychotics. Poster, 151. APA, Toronto, Canada

    Google Scholar 

  5. Bacher NM, Kaup BA (1996) Combining risperidone with standard neuroleptics for refractory schizophrenic patients. Am J Psychiatry 153: 137

    PubMed  CAS  Google Scholar 

  6. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F (1995) Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166: 68–72

    Article  PubMed  CAS  Google Scholar 

  7. Carpenter Jr WT, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11: 440–452

    Article  PubMed  Google Scholar 

  8. Carpenter WT (1991) Psychopathology and common sense. Biol Psychiatry 29: 735–737

    Article  PubMed  Google Scholar 

  9. Carriere P, Bonhomme D, Lemperiere T (2000) Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry 15: 321–329

    Article  PubMed  CAS  Google Scholar 

  10. Chabannes JP, Pelissolo A, Farah S, Gerard D (1998) Evaluation de l’efficacite et de la tolerance de l’amisulpride dans le traitement des psychoses schizophreniques. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses]. Encephale 24: 386–392

    PubMed  CAS  Google Scholar 

  11. Colonna L, Saleem P, Dondey-Nouvel L, Rein W (2000) Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 15: 13–22

    Google Scholar 

  12. Committee for Proprietary Medicinal Products [CPMP] (1998) Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Schizophrenia. The European Agency for the Evaluation of Medicinal Products, London

    Google Scholar 

  13. Conley RR, Kelly DL, Gale EA (1998) Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 33: 95–101

    Article  PubMed  CAS  Google Scholar 

  14. Cooper SJ, Raniwalla J, Welch C (1996) A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Eur Neuropsychopharmacol 6 (Suppl 3): 148

    Article  Google Scholar 

  15. Cooper SJ, Tweed J, Raniwalla J, Butler A, Welch C (2000) A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr Scand 101: 218–225

    Article  PubMed  CAS  Google Scholar 

  16. Costa-e-Silva JA (1990) A comparative double-blind trial of amisulpride versus haloperidol in the treatment of acute psychotic disorders [in French]. Ann Psychiatry 5 (1): 71–78

    Google Scholar 

  17. Coulouvrat C, Dondey-Nouvel L (1999) Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 14: 209–218

    Article  PubMed  CAS  Google Scholar 

  18. Curran MP, Perry CM (2001) Amisulpride: a review of its use in the management of schizophrenia. Drugs 61: 2123–2150

    Article  PubMed  CAS  Google Scholar 

  19. Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE, Pickar D, Lubick LJ, Williams TS (1996) Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 153: 417–419

    PubMed  CAS  Google Scholar 

  20. Danion JM, Rein W, Fleurot O (1999) Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 156: 610–616

    Google Scholar 

  21. Davis R, Markham A (1997) Ziprasidone. CNS Drugs 8 (2): 153–159

    Article  CAS  Google Scholar 

  22. Delcker A, Schoon ML, Oczkowski B, Gaertner HJ (1990) Amisulpride versus haloperidol in treatment of schizophrenic patients-results of a double-blind study. Pharmacopsychiatry 23: 125–130

    Article  PubMed  CAS  Google Scholar 

  23. Fleurot O, Martins S, Loo H, Peuskens J, Rein W (2002) Amisulpride vs olanzapine in schizophrenia. Preliminary results on short-term analysis. Eur Psychiatry 17 (Suppl 1): 107s

    Article  Google Scholar 

  24. Franz M, Gallhofer B (1997) Risperidon — ein neuer Serotonin-Dopamin-Antagonist zur Behandlung der Schizophrenie. Psychopharmakotherapie 2: 54–58

    Google Scholar 

  25. Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H (1996) Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 6: 13–20

    Google Scholar 

  26. Henderson DC, Nasrallah RA, Goff DC (1998) Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry 59: 585–588

    Article  PubMed  CAS  Google Scholar 

  27. Kirkpatrick B, Kopelowicz A, Buchanan RW, Carpenter WT (2000) Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. Neuropsychopharmacology 22: 303–310

    Article  PubMed  CAS  Google Scholar 

  28. Lecrubier Y, Benkert O, Kasper S et al. (2000) Amisulpride versus risperidone in schizophrenia: comparing clinical and functional outcome in a 6 month study [abstract no. 196]. 39th Annual Meeting of the American College of Neuropsychopharmacology, Dec 10–14 2000, San Juan

    Google Scholar 

  29. Lecrubier Y, Boyer P, Turjanski S, Rein W (1997) Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord 43: 95–103

    Google Scholar 

  30. Lee MA, Thompson PA, Meltzer HY (1994) Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 55 Suppl B: 82–87

    Google Scholar 

  31. Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002) Amisulpride, an unusual „Atypical“antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159: 180–190

    Article  PubMed  Google Scholar 

  32. Lindenmayer JP, Iskander A, Park M, Apergi FS, Czobor P, Smith R, Allen D (1998) Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry 59: 521–527

    Article  PubMed  CAS  Google Scholar 

  33. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O (1997) Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170: 18–22

    Article  PubMed  CAS  Google Scholar 

  34. Martin J, Gomez JC, Garcia BE, Cuesta M, Alvarez E, Gurpegui M (1997) Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. J Clin Psychiatry 58: 479–483

    Google Scholar 

  35. Meats P (1997) Quetiapine („Seroquel“); an effective and well-tolerated atypical antipsychotic. Int J Psych Clin Prac 1: 231–239

    Article  CAS  Google Scholar 

  36. Meltzer HY (1995) Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 3: 64–75

    PubMed  CAS  Google Scholar 

  37. Meltzer HY, Lee MA, Ranjan R (1994) Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr Scand Suppl 384: 95–101

    Article  PubMed  CAS  Google Scholar 

  38. Mountjoy CQ, Baldacchino AM, Stubbs JH (1999) British experience with high-dose olanzapine for treatment-refractory schizophrenia. Am J Psychiatry 156: 158–159

    PubMed  CAS  Google Scholar 

  39. Möller HJ (2000) Aktuelle Bewertung neuer/atypischer Neuroleptika. Nervenarzt 71: 329–344

    Article  PubMed  Google Scholar 

  40. Möller HJ (2001) Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. Eur Arch Psychiatry Clin Neurosci 251: 217–224

    Article  PubMed  Google Scholar 

  41. Möller HJ, Boyer P, Fleurot O, The PROD-ASLP Study Group (1997) Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with Haloperidol. Psychopharmacology 132: 396–401

    Google Scholar 

  42. Möller HJ, Müller H (1997) Statistical differentiation between direct and indirect effects of neuroleptics on negative symptoms. Eur Arch Psychiatry Clin Neurosci 247: 1–5

    Article  PubMed  Google Scholar 

  43. Möller HJ, Müller H, Borison RL, Schooler NR, Chouinard G (1995) A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenia patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 245: 45–49

    Google Scholar 

  44. Möller HJ, Müller WE, Bandelow B (2001) Neuroleptika. Pharmakologische Grundlagen, klinisches Wissen und therapeutisches Vorgehen. Wissenschaftliche Verlagsgesellschaft, Stuttgart

    Google Scholar 

  45. Möller HJ, van Praag HM, Aufdembrinke B, Bailey P, Barnes TR, Beck J, Bentsen H, Eich FX, Farrow L, Fleischhacker WW, Gerlach J, Grafford K, Hentschel B, Hertkorn A, Heylen S, Lecrubier Y, Leonhard JP, McKenna P, Maier W, Pedersen V, Rappard A, Rein W, Ryan J, Sloth Nielsen M, Stieglitz RD, Wegener G, Wilson J (1994) Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia. Psychopharmacology 115: 221–228

    Google Scholar 

  46. Müller N, Möller HJ (1999) Amisulprid in der Therapie schizophrener Negativsymptomatik. Psychopharmakotherapie 6 (Suppl 9): 15–19

    Google Scholar 

  47. Naber D, Lambert M, Krausz M (1999) Atypische Neuroleptika in der Behandlung schizophrener Psychosen. UNI-MED, Bremen

    Google Scholar 

  48. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995) Dl, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152: 1444–1449

    PubMed  CAS  Google Scholar 

  49. Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F (1995) Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152: 130–134

    PubMed  CAS  Google Scholar 

  50. Papp M, Wieronska J (2000) Antidepressant-like activity of amisulpride in two animal models of depression. J Psychopharmacol 14: 46–52

    Article  PubMed  CAS  Google Scholar 

  51. Peuskens J (2001) Efficacy of new antipsychotics on cognitive functions in schizophrenia. Eur Neuropsychopharmacol 11 (Suppl 3): S136 - S137

    Article  Google Scholar 

  52. Peuskens J, Bech P, Möller HJ, Bale R, Fleurot O, Rein W, Amisulpride study group (1999) Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 88: 107–117

    Article  PubMed  CAS  Google Scholar 

  53. Pichot P, Boyer P (1988) A double-blind, controlled, multicenter trial of amisulpride versus high dose haloperidol in acute psychotic disorders [in French]. Ann Psychiatry 3 (3): 326–332

    Google Scholar 

  54. Puech A, Fleurot O, Rein W (1998) Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand 98: 65–72

    Google Scholar 

  55. Reinbold H (2000) Gewichtszunahme unter Neuroleptika-Therapie. Psychopharmakotherapie 7: 15–17

    Google Scholar 

  56. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124: 57–73

    Article  CAS  Google Scholar 

  57. Sharma T, Mockler D (1998) The cognitive efficacy of atypical antipsychotics in schizophrenia. J Clin Psychopharmacol 18 (Suppl 1): 12S - 19S

    Article  PubMed  CAS  Google Scholar 

  58. Smeraldi E (1998) Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord 48: 47–56

    Article  PubMed  CAS  Google Scholar 

  59. Smith RC, Chua JW, Lipetsker B, Bhattacharyya A (1996) Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. J Clin Psychiatry 57: 460–466

    Article  PubMed  CAS  Google Scholar 

  60. Stanniland C, Taylor D (2000) Tolerability of atypical antipsychotics. Drug Saf 22: 195–214

    Article  PubMed  CAS  Google Scholar 

  61. Tanner TB, Ganguli R, Reddy R, Allen M, Field K (1995) Risperidone for treatment-refractory schizophrenia. Am J Psychiatry 152: 1233

    PubMed  CAS  Google Scholar 

  62. Tollefson GD, Kuntz AJ (1999) Review of recent clinical studies with olanzapine. Br J Psychiatry 37 (Suppl): 30–35

    Google Scholar 

  63. Tollefson GD, Sanger TM (1997) Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154: 466–474

    PubMed  CAS  Google Scholar 

  64. Tracy JI, Monaco CA, Abraham G, Josiassen RC, Pollock BG (1998) Relation of serum anti-cholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. J Clin Psychiatry 59: 184–188

    Article  PubMed  CAS  Google Scholar 

  65. Wehnert A, Mack R, Stilwell C, Rasmussen C, Silber C (1997) Direct Effect of Sertindole on the Primary Negative Symptoms of Schizophrenia: A PATH Analysis. Presented as Poster at the 6th World Congress of Biological Psychiatry, Nice, June 22–27

    Google Scholar 

  66. Wetzel H, Grunder G, Hillert A, Philipp M, Gattaz WF, Sauer H, Adler G, Schroder J, Rein W, Benkert O (1998) Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology — a double-blind controlled study comparing a selective D2-like antagonist to a mixed Dl-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl) 137: 223–232

    Google Scholar 

  67. Wolfersdorf M, Konig F, Straub R (1994) Pharmacotherapy of delusional depression: experience with combinations of antidepressants with the neuroleptic zotepine and haloperidol. Neuropsychobiology 29: 189–193

    Article  PubMed  CAS  Google Scholar 

  68. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB, The Sertindole Study Group (1997) Controlled, dose-response study of sertin-dole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154: 782–791

    CAS  Google Scholar 

  69. Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y, Amisulprid Study Group (2002) Amisulpride vs. Risperidone in chronic schizophrenia: results of a 6-months double-blind study. Neuropsychopharmacology 27: 1071–1081

    Article  PubMed  CAS  Google Scholar 

  70. Martin S, Loo H, Peuskens J, Thirumalai S, Gindicelli A, Fleurot O, Rein W (2002) A double-blind, randomised comparative trial of Amisulpride versus Olanzapine in the treatment of schizophrenia: short-term results at two months. Current Medical Research and Opinion 18: 355–362

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. H.-J. Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität München, Nußbaumstr. 7, 80336, München, Deutschland

    Hanns Hippius (em. o. Professor für Psychiatrie) (em. o. Professor für Psychiatrie)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Möller, HJ. (2003). Antipsychotische Wirksamkeit des atypischen Neuroleptikums Amisulprid auf Positiv- und Negativsymptomatik. In: Hippius, H. (eds) Universitätskolloquien zur Schizophrenie. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57417-7_37

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57417-7_37

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-642-63263-1

  • Online ISBN: 978-3-642-57417-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation